<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04141657</url>
  </required_header>
  <id_info>
    <org_study_id>07819001</org_study_id>
    <nct_id>NCT04141657</nct_id>
  </id_info>
  <brief_title>Safety Analysis of Antimicrobial Pharmacotherapy in Intensive Care Unit at Pediatric Hospital</brief_title>
  <official_title>Observational Prospective Multidirectional Study on the Safety of Antimicrobial Pharmacotherapy in Intensive Care Unit (ICU) Children Aged 0-17</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Vlasova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Russian Medical Academy of Continuous Professional Education</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Medical Research Center for Children's Health, Russian Federation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Changes in the metabolic ability of cytochrome P-450 during child development can affect both
      bioavailability and elimination depending on the involvement of intestinal and hepatic
      metabolic processes. The age-related variability of cytochrome P-450 isoenzymes in children
      has been described since 2010. The variability in the development of the activity of specific
      cytochrome P-450 isoenzymes illustrates why the pharmacogenetic features of the medicine use
      at different age periods should be studied for individual drugs. This will provide an
      understanding of the mechanisms for preventing adverse events appearing in pediatric
      intensive care units while more common antimicrobial pharmacotherapy is administered.
      Improved knowledge of the pharmacogenetic characteristics of cytochrome P-450 and the
      unintended consequences of modulation of its isoenzymes could provide an understanding of the
      susceptibility to adverse events in children in critical conditions staying at Intensive Care
      unit (ICU).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An observational prospective multidirectional study on the safety of antimicrobial
      pharmacotherapy in ICU children aged 0-17. The endpoints of the safety assessment are the
      frequency of adverse events with antimicrobial agents (AMA); electrocardiography (ECG),
      fibrinogen concentration, international normalized ratio (INR) and prothrombin index (IPT) at
      screening and at the end of the treatment course, and pharmacogenetic indicators (a more
      detailed study of the safety profile). A demonstration of the effectiveness of each of these
      comparisons of inequality will be based on the hypothesis testing approach, according to
      which the null hypothesis concludes that there is no difference between groups receiving
      different AMA combinations for the endpoint of interest; and an alternative hypothesis
      supposes a difference between treatment groups receiving different AMA combinations. Changes
      in the sequential organ failure assessment (SOFA) scale in dynamics compared to the baseline
      will be analyzed using the Mixed-Effect Model Repeated Measure (MMRM) model which assume the
      baseline, gender, age, AMA combination, and the duration of the AMA course. For a population
      of subjects aged 0-3 months, the analysis will be performed using the analysis of covariance
      (ANCOVA) model with the effects of INR, fibrinogen, and IPT values at the initial level for
      gender, age, and AMA combination in the treatment groups.

      To assess the secondary endpoint for the general population - the frequency and timing of the
      transition to de-escalation at ICU, cluster analysis will be conducted to identify the
      relationship of specific AMA combinations with the possibility of de-escalation in ICU
      children.

      Studies will be conducted to reveal the relationship in gene polymorphism encoding isoenzymes
      of the cytochrome P-450 biotransformation, and the relationship between the activity of
      transport proteins with the indicators of effectiveness and safety of antimicrobial
      pharmacotherapy. The lack of pharmacological safety studies in children administered medicine
      combinations to overcome pan-resistant gram-negative infection provides relevant
      prerequisites for this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events frequency</measure>
    <time_frame>From baseline until the date of first documented progression, assessed up to 1 month</time_frame>
    <description>Registered adverse events in participants during the treatment course</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG QT Interval change</measure>
    <time_frame>Change from screening QT Interval at 1 month</time_frame>
    <description>Assessment of QT Interval change at the end of the AMA course comparing with screening measurement</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Drug Therapy</condition>
  <arm_group>
    <arm_group_label>Group 1 (0-17 years)</arm_group_label>
    <description>We will observe the treatment course in ICU pediatric patients, register adverse events (AEs) and serious adverse events (SAEs) if occur, and assess patient health status at the end of the performed therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacogenetic test</intervention_name>
    <description>Buccal swabs are a relatively non-invasive way to collect deoxyribonucleic acid (DNA) samples for testing. A buccal swab will be performed to collect DNA from the cells on the inside of a subject's cheek for phenotyping of CYP3A4.</description>
    <arm_group_label>Group 1 (0-17 years)</arm_group_label>
    <other_name>Buccal swabs for pharmacogenetic testing</other_name>
    <other_name>buccal smear</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Genotyping of CYP2D6*4 (1846G&gt;A, rs3892097), CYP2C19*2 (681G&gt;A, rs4244285), CYP2C19*3
      (636G&gt;A, rs4986893), CYP2C19*17 (-806C&gt;T, rs12248560), CYP3A4*22 (15389C&gt;T, rs35599367),
      CYP3A5*3 (6986A&gt;G, rs77646), ABCB1 (3435C&gt;T, rs1045642) will be performed using real-time
      polymerase chain reaction (real-time PCR).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will enroll the participants from the patients of the Intensive Care Unit at the
        National Medical Research Center of Children's Health, Moscow, Russian Federation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Intensive Care Unit (ICU) patient;

          2. Community-acquired infections with risk factors for multidrug-resistant pathogens
             (risk factors for extended-spectrum β-lactamase (ESBL) — type II;

          3. Nosocomial infections — type III:

               -  IIIa: hospitalized during the period of 90 days, without prior antimicrobial
                  agent (AMA) therapy outside the ICU (risk factors for ESBL);

               -  IIIb: prolonged hospitalization (&gt; 7 days) and/or stay at ICU for more than 3
                  days and/or previous AMA therapy (risk factors for ESBL, carbenicillin-resistant
                  (CARB-R), nonfermenting Gram-negative bacteria (NFGNB), methicillin-resistant
                  Staphylococcus aureus (MRSA));

          4. Nosocomial infections with a risk of invasive candidiasis — type IV (candida score ≥2
             points);

          5. Written informed consent for medical intervention signed by at least one parent or
             caregiver (legal guardian) or informed consent of a patient under 15 years of age;

          6. Written informed consent for pharmacogenetic research signed by at least one parent or
             caregiver (legal guardian) or informed consent of a patient under 15 years of age.

        Exclusion Criteria:

          1. Type I: patients with community-acquired infections and without risk factors for
             multidrug-resistant pathogens, without hospitalization during the previous 90 days;

          2. Previous/concomitant therapy is not significant;

          3. Children in the ward: children under guardianship are not eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Vlasova, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Medical Research Center of Children's Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Vlasova, PhD, MD</last_name>
    <phone>+79051325629</phone>
    <email>annavlasova75@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anastacia Boliguzova</last_name>
    <phone>+79851522773</phone>
    <email>anboliguzova@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Morozov Children's City Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Vlasova, PhD, MD</last_name>
      <phone>+79051325629</phone>
      <email>annavlasova75@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Anna Vlasova, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://www.researchgate.net/publication/265553167_Hypofibrinogenaemia_associated_with_the_administration_of_tigecycline</url>
    <description>Karaiskos I, Barmpouti E, Ioannidis K, et al. Hypofibrinogenaemia associated with the administration of tigecycline. Conference Paper (poster). Conference: 24th ECCMID; 2014, Barcelona, Spain. doi: 10.13140/2.1.2337.2163.</description>
  </link>
  <link>
    <url>http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003750.pdf</url>
    <description>Guideline on the Investigation of Medicinal Products in the Term and Preterm Neonate. London, UK: European Medicines Agency; 2009.</description>
  </link>
  <link>
    <url>https://www.escmid.org/escmid_publications/escmid_elibrary/?q=Pharmacokinetics+in+various+patient+groups+In+vitro+investigations+on+the+atypical+protein&amp;id=2173&amp;L=0&amp;x=11&amp;y=14</url>
    <description>Kees F, Kratzer A, et al. In vitro investigations on the atypical protein binding behaviour of tigecycline using ultrafiltration. ECCMID; April 27 2015, Copenhagen, Denmark. Paper Poster Session V: Pharmacokinetics in various patient groups. P 1137.</description>
  </link>
  <link>
    <url>https://www.escmid.org/escmid_publications/escmid_elibrary/?q=Therapeutic+drug+monitoring+%28TDM%29-guided+continuous+infusion+&amp;id=2173&amp;L=0&amp;x=0&amp;y=0</url>
    <description>Daniel CR, Frey OR, Roehr A, et al. Therapeutic drug monitoring (TDM)-guided continuous infusion (CI) of piperacillin/tazobactam (PIP) reduces the mortality of critically ill patients in the intensive care unit (ICU). ECCMID Conference, 2019.</description>
  </link>
  <results_reference>
    <citation>Ward RM, Benjamin D, Barrett JS, Allegaert K, Portman R, Davis JM, Turner MA. Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates. Pediatr Res. 2017 May;81(5):692-711. doi: 10.1038/pr.2016.221. Epub 2016 Nov 3. Review.</citation>
    <PMID>28248319</PMID>
  </results_reference>
  <results_reference>
    <citation>Martinez Tadeo JA, Perez Rodriguez E, Almeida Sanchez Z, Callero Viera A, Garcia Robaina JC. No Cross-Reactivity With Cephalosporins in Patients With Penicillin Allergy. J Investig Allergol Clin Immunol. 2015;25(3):216-7.</citation>
    <PMID>26182689</PMID>
  </results_reference>
  <results_reference>
    <citation>Ball P. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother. 2000 May;45(5):557-9.</citation>
    <PMID>10797074</PMID>
  </results_reference>
  <results_reference>
    <citation>Schliamser SE, Broholm KA, Liljedahl AL, Norrby SR. Comparative neurotoxicity of benzylpenicillin, imipenem/cilastatin and FCE 22101, a new injectible penem. J Antimicrob Chemother. 1988 Nov;22(5):687-95.</citation>
    <PMID>3209527</PMID>
  </results_reference>
  <results_reference>
    <citation>Odio CM, Puig JR, Feris JM, Khan WN, Rodriguez WJ, McCracken GH Jr, Bradley JS. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediatr Infect Dis J. 1999 Jul;18(7):581-90.</citation>
    <PMID>10440432</PMID>
  </results_reference>
  <results_reference>
    <citation>Cui L, Kasegawa H, Murakami Y, Hanaki H, Hiramatsu K. Postoperative toxic shock syndrome caused by a highly virulent methicillin-resistant Staphylococcus aureus strain. Scand J Infect Dis. 1999;31(2):208-9.</citation>
    <PMID>10447337</PMID>
  </results_reference>
  <results_reference>
    <citation>Norrby SR. Carbapenems in serious infections: a risk-benefit assessment. Drug Saf. 2000 Mar;22(3):191-4. Review.</citation>
    <PMID>10738843</PMID>
  </results_reference>
  <results_reference>
    <citation>Winston DJ, Lazarus HM, Beveridge RA, Hathorn JW, Gucalp R, Ramphal R, Chow AW, Ho WG, Horn R, Feld R, Louie TJ, Territo MC, Blumer JL, Tack KJ. Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis. 2001 Feb 1;32(3):381-90. Epub 2001 Jan 30.</citation>
    <PMID>11170945</PMID>
  </results_reference>
  <results_reference>
    <citation>Karadeniz C, Oğuz A, Canter B, Serdaroğlu A. Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin. Pediatr Hematol Oncol. 2000 Oct-Nov;17(7):585-90.</citation>
    <PMID>11033734</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith RG. Penicillin and cephalosporin drug allergies: a paradigm shift. J Am Podiatr Med Assoc. 2008 Nov-Dec;98(6):479-88. Review.</citation>
    <PMID>19017859</PMID>
  </results_reference>
  <results_reference>
    <citation>Laughon MM, Avant D, Tripathi N, Hornik CP, Cohen-Wolkowiez M, Clark RH, Smith PB, Rodriguez W. Drug labeling and exposure in neonates. JAMA Pediatr. 2014 Feb;168(2):130-6. doi: 10.1001/jamapediatrics.2013.4208.</citation>
    <PMID>24322269</PMID>
  </results_reference>
  <results_reference>
    <citation>Setiawan E, Suwannoi L, Montakantikul P, Chindavijak B. Optimization of Intermittent Vancomycin Dosage Regimens for Thai Critically Ill Population Infected by MRSA in the Era of the &quot;MIC Creep&quot; Phenomenon. Acta Med Indones. 2019 Jan;51(1):10-18.</citation>
    <PMID>31073101</PMID>
  </results_reference>
  <results_reference>
    <citation>León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, Garnacho-Montero J, León MA; EPCAN Study Group. A bedside scoring system (&quot;Candida score&quot;) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006 Mar;34(3):730-7.</citation>
    <PMID>16505659</PMID>
  </results_reference>
  <results_reference>
    <citation>Prot-Labarthe S, Weil T, Angoulvant F, Boulkedid R, Alberti C, Bourdon O. POPI (Pediatrics: Omission of Prescriptions and Inappropriate prescriptions): development of a tool to identify inappropriate prescribing. PLoS One. 2014 Jun 30;9(6):e101171. doi: 10.1371/journal.pone.0101171. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e108007.</citation>
    <PMID>24978045</PMID>
  </results_reference>
  <results_reference>
    <citation>Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011 Sep;66(9):1963-71. doi: 10.1093/jac/dkr242. Epub 2011 Jun 18. Review.</citation>
    <PMID>21685488</PMID>
  </results_reference>
  <results_reference>
    <citation>McGovern PC, Wible M, El-Tahtawy A, Biswas P, Meyer RD. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents. 2013 May;41(5):463-7. doi: 10.1016/j.ijantimicag.2013.01.020. Epub 2013 Mar 26.</citation>
    <PMID>23537581</PMID>
  </results_reference>
  <results_reference>
    <citation>Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E; Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S341-53.</citation>
    <PMID>16080072</PMID>
  </results_reference>
  <results_reference>
    <citation>Baietto L, Corcione S, Pacini G, Perri GD, D'Avolio A, De Rosa FG. A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? Curr Drug Metab. 2014;15(6):581-98. Review.</citation>
    <PMID>24909419</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol. 2004 Oct;44(10):1083-105. Review.</citation>
    <PMID>15342610</PMID>
  </results_reference>
  <results_reference>
    <citation>Matthews HW. Racial, ethnic and gender differences in response to medicines. Drug Metabol Drug Interact. 1995;12(2):77-91. Review.</citation>
    <PMID>8591695</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Medical Research Center for Children's Health, Russian Federation</investigator_affiliation>
    <investigator_full_name>Anna Vlasova</investigator_full_name>
    <investigator_title>PhD, chief of Clinical Pharmacology department</investigator_title>
  </responsible_party>
  <keyword>neonates</keyword>
  <keyword>antimicrobial pharmacotherapy</keyword>
  <keyword>pharmacotherapy adverse events</keyword>
  <keyword>neonatal Intensive Care Unit</keyword>
  <keyword>safety</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data will be made available partially upon a request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available within 6 months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Data Access Requests will be reviewed by the Independent Local Review Board. Requestors will be required to sign a Data Access Agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

